No News, # Pouches :)It would seem that some BB posters have little ability to assemble some self evident facts to draw applicable conclusions.
Sernova, a penny junior, is holding the line on the share price better than the general markets. This is indicative of good things. This suggests:
1) There is almost assuredly more than one pouch installed. Sernova has the money from the last PP and good results from cohort #1. To entice interested parties, Sernova has to install more pouches. That said, there is no requirement to issue news.
2) This is a FDA trial. Typically, news is scant from these types of trials. Please remember that CTI is running the show with the FDA. Checking the backgrounds on CTI employees shows they have close connections with the FDA and understand how information should be released, or not. CTI will ensure matters are always above board. This will help to expedite any developments with Big Pharma whether collaboration, or Buy, Bye.
Personally, I would love lots of news, but the historical pattern to date shows that Sernova is slow to issue news and downplays the information when it does, i.e. news is presented in a non-promotional, scientific manner. My take, in this COVID-19 trading environment, is Sernova is happy that there is enough daily interest that the share price is getting a bid. Readers will know, especially for Penny Juniors, some stocks are seizing up because of COVID-19. One can also conclude that Sernova should expect the share price to be weak with the general markets until it isn't (think substantial news).
I also believe that Sernova is continuing to demonstrate what
The Pouch is all about (
an artificial organ that can treat many different ailments). Once there is enough data (think from this FDA trial) the game will change. I believe that interested parties are still in the late stages of the "Show Me" phase.
If one thinks about it, and even if Sernova wanted to issue some regular news, the company is likely to be thinking why fire news bullets now? News will probably produce little reaction because of COVID-19's affect on the weak general markets.
Look what happened with news historically in a better general market environment: a pop followed by the goon squad massaging the share price back down. The present share price and trading volume suggest strongly that Sernova is Big Picture AOK... firing on all cylinders!
Historical News for CTI and Mackie (house 083):
LONDON, ONTARIO--(Marketwired - Nov. 2, 2016) - Sernova Corp. (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia and CTI Clinical Trial and Consulting Services (CTI), are pleased to announce their collaboration on regulatory matters respecting Sernova's Cell Pouch System™, a novel implantable and scalable medical device that when combined with therapeutic cells, may provide a convenient, safe and effective long-term therapeutic option for patients with chronic diseases such as insulin-dependent diabetes who seek to improve their quality of life.
CTI as an expert in cell therapy, and immunology among other life-changing therapies in critically and chronically ill patients is supporting Sernova's clinical trial regulatory processes including submission of Sernova's regulatory package with the FDA for the recently announced JDRF supported clinical trial in patients with insulin-dependent diabetes. In this regard CTI has been a part of more than 100 drug and device approvals and has proven success in advancing numerous international drug and device applications.
"We are really enthused to be collaborating with Sernova on filing their Investigational New Drug (IND) application with the US FDA," stated Timothy Schroeder, CTI Founder and CEO. "Sernova is an innovative organization with a regenerative medicine program that could change the standard of care for many chronically ill patients."
"We are pleased to have CTI supporting Sernova's clinical trial regulatory processes as they bring proven expertise in medical device and regenerative medicine technologies targeting chronically ill patient populations," remarked Dr. Philip Toleikis, Sernova President and CEO. "We at Sernova see this collaboration as the beginning of a long-term relationship in supporting the clinical development progression of our therapeutic cell and device applications. With their clinical trial experience across six continents in bringing research sites, patients, and sponsors together, CTI will be an invaluable member of Sernova's development team."
In further developments, Sernova also announced that it has retained Mackie Research Capital Corporation ("Mackie") to provide market making services to the company in compliance with the guidelines of the TSX Venture Exchange (the "TSXV"). Mackie will trade shares of Sernova on the TSXV for the purposes of maintaining an orderly market and improving the liquidity of Sernova's shares. In consideration for their services, Sernova has agreed to pay Mackie $3,000 per month for a period of 12 months which is extendable. The agreement may be terminated at any time by Sernova or Mackie. There are no performance factors contained in the agreement and Mackie will not receive any shares or options from Sernova as compensation for the services. Sernova and Mackie are unrelated and unaffiliated entities, but Mackie and/or its clients may have an interest, directly or indirectly, in the securities of Sernova. The agreement is subject to approval of the TSXV.
n.b. Note that Mackie is used to create an orderly trading market for Sernova shares. jwall 